Companies to create novel antibody therapeutics to treat fibrosis across a broad range of indications

公司开发新型抗体疗法，用于治疗广泛适应症中的纤维化

Ono to leverage Mediar's expertise in antibody discovery and harness its deep understanding of myofibroblast biology to develop a new class of multimodal therapies

小野制药将利用Mediar在抗体发现方面的专业知识，并借助其对肌成纤维细胞生物学的深刻理解，开发一类新型多模式疗法

BOSTON

波士顿

,

，

Aug. 6, 2026

2026年8月6日

/PRNewswire/ --

/PRNewswire/ --

Mediar Therapeutics, Inc.

Mediar Therapeutics, Inc.

, a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, has entered into a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; 'Ono') for novel treatments targeting fibro-inflammatory diseases.

，一家处于临床阶段的生物技术公司，致力于开创首创新药以遏制并逆转纤维化，已与ONO制药株式会社（总部：日本大阪；总裁兼首席运营官：Takino Toichi；简称“Ono”）达成合作与选择权协议，共同开发针对纤维炎症性疾病的新型疗法。

These diseases are characterized by myofibroblast activation, scarring, inflammation and tissue remodeling, which can lead to organ failure and complications..

这些疾病的特征是肌成纤维细胞活化、瘢痕形成、炎症和组织重塑，可能导致器官衰竭和并发症。

Under the terms of the agreement, Ono will partner with Mediar, leveraging the company's fibrosis-focused discovery platform, myofibroblast expertise, and understanding of key fibrosis pathways. Ono will have an exclusive option to license worldwide rights to develop and commercialize the programs, making an upfront payment to Mediar, and supporting R&D costs..

根据协议条款，小野制药将与Mediar合作，利用该公司专注于纤维化的发现平台、肌成纤维细胞专业知识以及对关键纤维化通路的理解。小野制药将获得独家选择权，以许可全球范围内的开发和商业化权利，并向Mediar支付预付款，同时支持研发费用。

'This strategic collaboration with Ono is an important milestone for Mediar and reflects the growing recognition that directly targeting the myofibroblast can unlock new therapeutic possibilities in fibrotic diseases,' said Rahul Ballal, Ph.D., Chief Executive Officer of Mediar Therapeutics. 'By using our expertise in fibrosis discovery, we are positioned to advance new potential therapies across a broad range of diseases.

Mediar Therapeutics 首席执行官 Rahul Ballal 博士表示：“此次与 Ono 的战略合作是 Mediar 的一个重要里程碑，也反映出业界日益认识到，直接靶向肌成纤维细胞能够为纤维化疾病开辟新的治疗可能性。凭借我们在纤维化研究领域的专业优势，我们有望在多种疾病领域推进新的潜在疗法。”

We are excited to start work with Ono Pharma after longstanding support from Ono Venture Investment, Inc. (OVI), who have been investors in the company since 2021.'.

我们很高兴在Ono Venture Investment, Inc.（OVI）长期支持下，开始与Ono Pharma合作。OVI自2021年以来一直是该公司的投资者。

'Fibro-inflammatory diseases remain areas of significant unmet medical need, and we believe biologics innovation is essential to provide meaningful therapeutic advances,' said Seishi Katsumata, Corporate Officer / Executive Vice President, Discovery & Research of Ono. 'Mediar has established deep scientific expertise in fibrosis and antibody discovery.

“纤维炎症性疾病仍然是存在重大未满足医疗需求的领域，我们认为生物制剂的创新对于提供有意义的治疗进展至关重要。”小野制药公司企业高管兼发现与研究执行副总裁Seishi Katsumata表示。“Mediar在纤维化和抗体发现领域建立了深厚的科学专业知识。”

By combining Mediar's capabilities with Ono's experience in immunology and inflammation research area, we aim to create novel antibody therapeutics that may offer new treatment options for patients.'.

通过将Mediar的技术能力与Ono在免疫学和炎症研究领域的经验相结合，我们旨在开发新型抗体疗法，为患者提供新的治疗选择。

Beyond the collaboration, Mediar will continue to advance its portfolio of first-in-class programs targeting fibrotic disorders including, MTX-474, an EphrinB2-targeting antibody in Phase 2 development for systemic sclerosis, MTX-463, an anti-WISP1 antibody in Phase 2 development for idiopathic pulmonary fibrosis in collaboration with Eli Lilly and Company and MTX-439, an anti-SMOC2 antibody in Phase 1 development for chronic kidney disease-mediated fibrosis..

除合作外，Mediar 将继续推进其针对纤维化疾病的首创药物组合，包括：MTX-474，一种靶向 EphrinB2 的抗体，目前处于治疗系统性硬化症的二期开发阶段；MTX-463，一种抗 WISP1 抗体，在与礼来公司（Eli Lilly and Company）的合作中处于治疗特发性肺纤维化的二期开发阶段；以及 MTX-439，一种抗 SMOC2 抗体，目前处于治疗慢性肾病介导纤维化的一期开发阶段。

About MTX-474

关于MTX-474

MTX-474 is a first-in-class human IgG1 antibody designed to neutralize the EphrinB2 signaling that causes the onset and progression of fibrosis. Ephrin ligands and Eph receptors mediate biological processes involved in tissue fibrosis including cell migration, myofibroblast activation, and tissue remodeling.

MTX-474 是一款首创的人源 IgG1 抗体，旨在中和导致纤维化发生和进展的 EphrinB2 信号传导。Ephrin 配体与 Eph 受体介导了参与组织纤维化的生物过程，包括细胞迁移、肌成纤维细胞活化以及组织重塑。

A growing body of evidence has implicated EphrinB2 in the fibrosis of the skin, lungs, and heart. Expression of EphrinB2 and its receptors is measurable in human blood and correlates with disease severity. A Phase 1 study was recently completed and a Phase 2 clinical study in patients with systemic sclerosis is now open (NCT07287670).

越来越多的证据表明，EphrinB2 与皮肤、肺和心脏的纤维化有关。EphrinB2 及其受体的表达可在人体血液中检测到，并与疾病严重程度相关。一项 I 期研究最近已完成，针对系统性硬化症患者的 II 期临床研究现已启动（NCT07287670）。

More information can be found at .

更多信息请参见。

www.encompassctrial.com

www.encompassctrial.com

.

。

About MTX-463

关于 MTX-463

MTX-463 is a first-in-class human IgG1 antibody developed against WNT1-inducible signaling pathway protein-1 (WISP1). WISP1 is a secreted matricellular protein shown to have a relevant role in fibrosis progression, is measurable in human blood, and correlates with disease severity. Data indicates that MTX-463 neutralizes WISP1-mediated fibrotic signaling and significantly reduces fibrosis in vitro and in various preclinical models.

MTX-463 是一种首创的人源 IgG1 抗体，靶向 WNT1 诱导信号通路蛋白 1（WISP1）。WISP1 是一种分泌型基质细胞蛋白，已被证实与纤维化进展密切相关，可在人血中检测，且其水平与疾病严重程度相关。数据显示，MTX-463 可中和 WISP1 介导的纤维化信号传导，并在体外及多种临床前模型中显著减轻纤维化。

A Phase 2 study in patients with idiopathic pulmonary fibrosis is now recruiting (NCT06967805). More information can be found at .

一项针对特发性肺纤维化患者的二期研究正在招募受试者（NCT06967805）。更多信息请访问。

www.wispertrial.com

www.wispertrial.com

.

。

About MTX-439

关于MTX-439

MTX-439 is a first-in-class human IgG1 antibody developed to neutralize the activity of SMOC2, a secreted matricellular protein implicated in the pathogenesis and progression of kidney fibrosis. SMOC2's expression correlates with disease severity in CKD and is measurable in patient samples, supporting its utility as both a therapeutic target and a precision biomarker.

MTX-439 是一款首创的人源 IgG1 抗体，旨在中和分泌型基质细胞蛋白 SMOC2 的活性，该蛋白与肾纤维化的发病机制及进展密切相关。SMOC2 的表达水平与慢性肾脏病（CKD）的疾病严重程度相关，且可在患者样本中检测，这支持其作为治疗靶点以及精准生物标志物的应用价值。

Preclinical studies have demonstrated that MTX-439 can disrupt profibrotic SMOC2-mediated signaling and significantly reduce fibrosis in human disease models. The current Phase 1 trial (NCT07473323) encompasses both healthy participants and adults with diabetic kidney disease, with plans to progress to a randomized Phase 2 program with clinical endpoints..

临床前研究表明，MTX-439 能够破坏促纤维化的 SMOC2 介导信号通路，并在人类疾病模型中显著减轻纤维化。目前的 I 期临床试验（NCT07473323）纳入了健康受试者和糖尿病肾病患者，计划推进至具有临床终点的随机 II 期研究项目。

About Mediar Therapeutics

关于Mediar Therapeutics

Mediar Therapeutics

Mediar 治疗公司

is pioneering a new approach to fibrosis treatment that halts the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and progression.

正在开创一种治疗纤维化的新方法，从不同的源头遏制疾病——肌成纤维细胞。肌成纤维细胞是纤维化中的关键致病细胞，驱动瘢痕形成、疾病进展，并最终导致器官衰竭。Mediar 的成立基于对纤维化发病和进展背后复杂科学的深刻理解。

By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development. For more information, contact .

通过将新颖靶点与可靠、易于检测的血液生物标志物及熟悉的给药方式相结合，Mediar 正在降低纤维化疗法在临床开发过程中的风险。如需更多信息，请联系。

[email protected]

[email protected]

or follow us on

或在以下平台关注我们

LinkedIn

领英

.

。

Mediar Therapeutics

Mediar Therapeutics

Email:

电子邮件：

[email protected]

[email protected]

SOURCE Mediar Therapeutics

来源：Mediar Therapeutics

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示